Notizie AIOM – anno XVII
Fear of Cancer Recurrence: A Model Examination of Physical Symptoms, Emotional Distress, and Health Behavior Change
Fear of cancer recurrence is highly prevalent among adult survivors of cancer. The role of fear of recurrence in the emotional distress of survivors of cancer, as well as health behaviors that may directly affect their health, remains unclear. To advance oncology practice, ...Leggi tutto
Has the Quality of Patient-Provider Communication About Survivorship Care Improved?
The aim of the current study was to assess whether the quality of patient–provider communication on key elements of cancer survivorship care changed between 2011 and 2016. Participating survivors completed the 2011 or 2016 Medical Expenditure Panel Survey Experiences ...Leggi tutto
No Man Is an Island: Reflections From an ASCO IDEA Recipient
July 25, 2019 - IT WAS a chilly Chicago morning, and I was sitting at the lobby of my hotel when I saw a smiling gentleman cheerfully waving at me from his car. It was Lawrence H. Einhorn, MD, picking me up for our drive to Indiana. I was one of the recipients of the ASCO ...Leggi tutto
How the ASCO Breakthrough Global Summit Is Bringing Together Innovators to Transform Cancer Care
July 25, 2019 - Earlier this year, ASCO announced plans for its first-ever international meeting, ASCO Breakthrough: A Global Summit for Oncology Innovators, which will be held October 11–13, 2019, in Bangkok, Thailand. The meeting is a joint effort by ASCO and the ...Leggi tutto
FDA launches its first youth e-cigarette prevention TV ads, plans new educational resources as agency approaches one-year anniversary of public education campaign
July 22, 2019 - Today, the U.S. Food and Drug Administration is announcing the launch of its first e-cigarette prevention TV ads educating kids about the dangers of e-cigarette use. The FDA also plans to provide new posters for high schools and educational materials for ...Leggi tutto
Searching for Novel Agents to Augment Atezolizumab Approval in Small Cell Lung Cancer
July 22, 2019 - Despite the integration of frontline immunotherapy into routine practice for patients with extensive-stage small cell lung cancer (SCLC), researchers are still searching for agents with a high clinical impact that do more than fill a space of unmet need, ...Leggi tutto
FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety
July 23, 2019 - Today, the U.S. Food and Drug Administration announced that it has issued a warning letter to Curaleaf Inc., of Wakefield, Massachusetts, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products ...Leggi tutto
FDA Grants Breakthrough Designation to Frontline Pembrolizumab/Lenvatinib for HCC
July 23, 2019 - The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab and lenvatinib for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma (HCC) that is not amenable to locoregional therapy. The ...Leggi tutto
FDA Approves Rituximab Biosimilar for CD20+ B-Cell Non-Hodgkin Lymphoma and CLL
July 23, 2019 - The FDA has approved PF-05280586 (rituximab-pvvr), a biosimilar for rituximab, for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy, or for patients with CD20-positive chronic ...Leggi tutto